<DOC>
	<DOCNO>NCT00598338</DOCNO>
	<brief_summary>The purpose study determine whether prucalopride safe effective re-treatment chronic constipation . Hypothesis : Retreatment effective safe treatment prucalopride patient chronic constipation .</brief_summary>
	<brief_title>Efficacy Safety Study Prucalopride Re-Treatment Chronic Constipation</brief_title>
	<detailed_description>This multicentre , Phase III trial parallel-group design , consist 2 week drug-free run-in period , follow 4-week double-blind , placebo-controlled treatment period , drug-free washout period least 2 week , second 4-week double-blind treatment period . During initial run-in period , subject 's bowel habit document daily diary existence constipation confirm . Eligible subject randomly allocate double-blind treatment either 4 mg prucalopride placebo , give orally daily breakfast , 4 week . After 4 week treatment , subject enter drug-free washout period . The length washout period either 2 4 week , depend long take subject meet criterion constipation . If subject unable re-qualify 4-week washout , subject must discontinue trial . Subjects qualify second double-blind treatment period receive treatment first treatment period , once-daily additional four week .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Male nonpregnant , nonbreastfeeding female outpatient least 18 year age ( upper age limit ) . 2 . History constipation ; patient report , average , 2 few spontaneous bowel movement per week result feeling complete evacuation well occurrence one follow least 6 month selection visit : hard ( little ball ) and/or hard stool least quarter stool ; sensation incomplete evacuation follow least quarter stool ; strain defecation least quarter time . The criterion applicable spontaneous bowel movement , i.e . precede within period 24 hour intake laxative agent use enema . Patients never spontaneous bowel movement consider constipate eligible study . 3 . Having functional constipation . Constipation induce secondary cause constipation ( see exclusion criterion 1 7 ) . 4 . Willing able fill his/her diary questionnaire without help , able read write English . 5 . Written informed consent , sign patient legally acceptable representative investigator . 6 . Availability followup study period determine protocol . 1 . Patients constipation think druginduced , use disallow medication 2 . Patients insulindependent diabetes mellitus . 3 . Patients suffer endocrine disorder . 4 . Patients suffer neurologic disorder 5 . Presence megacolon/megarectum diagnosis pseudoobstruction . 6 . Constipation result surgery . 7 . Known suspected organic disorder large bowel ( i.e . obstruction , carcinoma , inflammatory bowel disease ) . Results barium enema flexible sigmoidoscopy colonoscopic examination perform within last 12 month need rule organic disorder . A colonoscopic examination barium enema flexible sigmoidoscopy perform within last 3 year acceptable examination perform evaluation constipation , history evidence weight loss , anaemia , rectal bleeding , patient 3 consecutively negative stool occult blood test screen . Patients polyps discover colonoscopy untreated ( i.e . polypectomy ) exclude . 8 . Presence know serious , uncontrolled illness : clinically significant cardiac , vascular , pulmonary , endocrine , psychiatric disorder ( include active alcohol drug abuse ) metabolic disturbance . 9 . Clinically significant cancer within past 5 year . 10 . Subjects know HIV positive . 11 . Impaired renal function , i.e . serum creatinine concentration &gt; 2 mg/dL ( &gt; 180 micromol/L ) creatinine clearance ≤50 mL/min . 12 . Clinically significant abnormality haematology , urinalysis , blood chemistry . 13 . Females childbearing potential without adequate contraceptive protection study . Oral contraceptive , Depo Provera® Norplant® use least 3 month prior randomisation . Intrauterine device ( IUDs ) , sterilization , double barrier method acceptable method birth control . 14 . Treatment investigational drug 30 day precede runin phase study . 15 . Previous treatment either prucalopride formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>